BeBetter Med

BeBetter Med develops targeted small molecules and siRNA therapeutics across three platforms: small-molecule inhibitors, peptide-drug conjugates, and tissue-targeted siRNA delivered through its GDOC and POC conjugation systems. Its pipeline spans cancer, metabolic disease, renal disease and neurodegenerative disease, and its commercial product is ifupinostat (BEBT-908), a dual HDAC/PI3Kα inhibitor approved in China for relapsed or refractory diffuse large B-cell lymphoma.

Its siRNA programs address liver, central nervous system and kidney targets, including BEBT-701, which acts on both angiotensinogen and PCSK9 in hypertension with elevated LDL cholesterol. The small-molecule pipeline pairs selective inhibitors such as BEBT-209, described as having about six-fold greater CDK4 than CDK6 activity, with pan-mutant EGFR and pan-PPAR candidates. The company offers out-licensing, co-development and regional alliances across those platforms to partners working in oncology, cardio-metabolic, central nervous system and renal disease.